Fate sees positive B-cell lymphoma data at #ASCO21; ImaginAb secures funding for CD8 imaging trials

Fate Therapeutics revealed some new data at #ASCO21 for their R/R B-cell lymphoma program on Friday.

The San Diego biotech said interim Phase I data for FT516 revealed eight of 11 patients as of the March cutoff date had achieved an objective response, including six who...

Click to view original post